4,288
Views
7
CrossRef citations to date
0
Altmetric
Report

An integrated approach for characterizing immunogenic responses toward a bispecific antibody

, ORCID Icon, ORCID Icon, , , , , ORCID Icon, , , , , , & ORCID Icon show all
Article: 1944017 | Received 09 Apr 2021, Accepted 14 Jun 2021, Published online: 05 Jul 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Kathryn Ball, Simon J Dovedi, Pavan Vajjah & Alex Phipps. (2023) Strategies for clinical dose optimization of T cell-engaging therapies in oncology. mAbs 15:1.
Read now
Arthur J. Schick$suffix/text()$suffix/text(), Victor Lundin, Justin Low, Kun Peng, Richard Vandlen & Aaron T. Wecksler. (2022) Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody. mAbs 14:1.
Read now
Desislava Yanakieva, Lukas Pekar, Andreas Evers, Markus Fleischer, Stephan Keller, Dirk Mueller-Pompalla, Lars Toleikis, Harald Kolmar, Stefan Zielonka & Simon Krah. (2022) Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities. mAbs 14:1.
Read now

Articles from other publishers (3)

Punit Upadhyaya, Julia KristenssonJohanna Lahdenranta, Elizabeth Repash, Jun Ma, Jessica Kublin, Gemma E. Mudd, Lia Luus, Phil JeffreyKristen Hurov, Kevin McDonnell & Nicholas Keen. (2022) Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology. Journal of Medicinal Chemistry 65:14, pages 9858-9872.
Crossref
Shun‐Yu Wu, Fu‐Gen Wu & Xiaoyuan Chen. (2022) Antibody‐Incorporated Nanomedicines for Cancer Therapy. Advanced Materials 34:24.
Crossref
Rajbharan Yadav, Siddharth Sukumaran, Tanja S. Zabka, Jinze Li, Amy Oldendorp, Gary Morrow, Arthur Reyes, Melissa Cheu, Jessica Li, Jeffrey J. Wallin, Siao Tsai, Laura Sun, Peiyin Wang, Diego Ellerman, Christoph Spiess, Andy Polson, Eric G. Stefanich, Amrita V. Kamath & Meric A. Ovacik. (2022) Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies. Pharmaceutics 14:5, pages 970.
Crossref